Evidence map›Paper›PMID 36647342›Full record

ArticleCancer medicine2023

"There's not enough studies": Views of black breast and ovarian cancer patients on research participation.

Kirsten A Riggan, Abigail Rousseau, Michele Halyard, Sarah E James, Marion Kelly, Daphne Phillips, Megan A Allyse

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Engaging Patient Advocates to Reduce Breast Cancer Disparities: Opportunities to Advance Breast Cancer Research and Engagement.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kirsten A RigganBiomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-0127-9555
Abigail RousseauBiomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-6248-1829
Michele HalyardDepartment of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA.ORCID 0000-0003-0998-4600
Sarah E JamesDepartment of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA.
Marion KellyCoalition of Blacks Against Breast Cancer, Phoenix, Arizona, USA.
Daphne PhillipsADVANCE Community Advisory Board, Phoenix, Arizona, USA.
Megan A AllyseBiomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6136-9256
Mayo Clinic · USWinnMed · USAdvisory Board Company (United States) · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
NCATS NIH HHS UL1 TR002377NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201NCI NIH HHS P50 CA136393
6 · The paper itself

Abstract

backgroundBlack breast and ovarian cancer patients are underrepresented in clinical cancer trials disproportionate to the prevalence of these cancers in Black females. Historically, lower enrollment has been attributed to individualized factors, including medical mistrust, but more recently structural factors, including systemic racism, have received additional scrutiny. We interviewed Black women with a personal or family history of breast and ovarian cancer to understand their views and experiences related to research participation.

methodsQualitative interviews were conducted via telephone or video conference and transcribed verbatim. Transcripts were qualitatively analyzed for iterative themes related to the offer and participation in cancer clinical trials and research studies, impact on cancer care, and recommendations to increase enrollment of Black patients.

resultsSixty-one Black women completed an interview. Participants expressed that Black women are underrepresented in cancer research, and that this negatively impacted their own care. Many cited past historical abuses, including the Tuskegee syphilis trial, as a potential factor for lower enrollment but suggested that lower enrollment was better understood in the context of the entirety of their healthcare experiences, including present-day examples of patient mistreatment or dismissal. Participants suggested that proactive community engagement, transparency, and increased representation of Black research team members were strategies likely to foster trust and bolster research participation. CONCLUSION(S): Medical mistrust is only a partial factor in the lower participation of Black patients in cancer research. Researchers should implement the strategies identified by our participants to promote diverse enrollment and ensure that Black patients are included in future therapeutic advances.

Indexed as

Ovarian NeoplasmsTrustBlack or African AmericanBreast NeoplasmsClinical Trials as TopicFemaleHumansPatient ParticipationQualitative ResearchResearch Subjectsbreast cancerclinical cancer researchcommunity outreachwomen's cancer

Identifiers

PMID36647342
PMCPMC10134334
OpenAlexW4316928572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.